Frank L. Jaksch, Jr. has been a key figure in the biotechnology field since he founded ChromaDex Corporation in 2010. With a background in biology and a passion for health science, he has dedicated his career to developing innovative solutions...

Frank L. Jaksch, Jr. has been a key figure in the biotechnology field since he founded ChromaDex Corporation in 2010. With a background in biology and a passion for health science, he has dedicated his career to developing innovative solutions in wellness and aging. In June 2018, he transitioned from CEO to Executive Chairman, continuing to guide the company's strategic direction after a successful tenure. Under his leadership, ChromaDex achieved remarkable milestones, including significant increases in net sales and modifications to its stock structure, showcasing his ability to adapt and grow in a competitive landscape. Notably, Jaksch's insider trading activity showed impressive fluctuations in his holdings, peaking at values exceeding $11 million during a strong growth phase. His compensation reflected a performance-driven approach, with his 2018 package totaling nearly $850,000, including a substantial bonus linked to sales targets. Remarkably, he has been active in securing the company's future, participating in various organizational changes that align with broader market trends. This focus on performance and innovation highlights Jaksch's commitment to not just leading but also to ensuring ChromaDex's long-term viability.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ChromaDex CEOs

C

Frank L. Jaksch, Jr.

Ex-CEO of ChromaDex

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of ChromaDex for

1 year 9 months (Apr 2010 - Jan 2012)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Frank L. Jaksch, Jr.

Holdings

See how much did Frank L. Jaksch, Jr. make over time.

Frank L. Jaksch, Jr. has had significant insider trading activity throughout his career at ChromaDex. At one point, his holdings surged to over $11 million in September 2020, reflecting his strong financial ties to the company’s performance. However, since mid-2021,...

Frank L. Jaksch, Jr. has had significant insider trading activity throughout his career at ChromaDex. At one point, his holdings surged to over $11 million in September 2020, reflecting his strong financial ties to the company’s performance. However, since mid-2021, there has been a noticeable decline in the value of his holdings, dropping to the low millions by 2023. This fluctuation underscores the volatility in biotech stocks and indicates how market dynamics can impact personal wealth. Jaksch's net worth corresponding with his holdings has been closely tied to ChromaDex’s success in achieving key performance targets and innovations in product offerings. His strategic decision-making has not only influenced corporate direction but has also played a significant role in how his financial interests are realized in the competitive biotech market.

Total Stock Sold

$1.13M

CDXC

$1.13M

201,211 CDXC shares

What if they kept their stock?

If Frank L. Jaksch, Jr. didn't sell their stock, today they would have:
Extra CDXC201,211 shares worth $700.21K.
This is -38.21% and $432.91K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Frank L. Jaksch, Jr..

CDXC

$229.96K

CDXC at $6.19/share

Dec 13, 2024

Sale

CDXC

$11.83K

CDXC at $1.69/share

Jun 12, 2023

Purchase

CDXC

$196.33K

CDXC at $5.19/share

Dec 10, 2020

Sale

CDXC

$50.37K

CDXC at $3.50/share

Mar 11, 2019

Sale

CDXC

$35.13K

CDXC at $3.59/share

May 15, 2018

Purchase

CDXC

$2.18K

CDXC at $4.60/share

Mar 29, 2018

Sale

CDXC

$113.06K

CDXC at $4.60/share

Mar 27, 2018

Sale

CDXC

$184.75K

CDXC at $6.51/share

Jan 10, 2018

Sale

CDXC

$361.50K

CDXC at $6.19/share

Dec 21, 2017

Sale

CDXC

$4.84K

CDXC at $2.42/share

Dec 12, 2016

Purchase

Compensation History

See how much did Frank L. Jaksch, Jr. make over time.

In 2018, Frank L. Jaksch, Jr. received a total compensation package of about $847,451, which included a base salary of $379,121 and a bonus of $468,330 based on successful sales performance. His compensation aligns with ChromaDex’s growth trajectory, emphasizing a model where leadership financial rewards are closely tied to company performance. Throughout his time with ChromaDex, his compensation has varied, but notably, it reflects the company's performance-driven philosophy, aiming to attract and retain top talent in the competitive biotech sector. With total compensation packages ranging from under $500,000 in earlier years to nearly $850,000 in peak performance years, Jaksch's pay illustrates a clear correlation between the company’s success and its executive remuneration.

Year

2018

Total Compensation

$1.47M

Salary

$379.12K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on performance metrics related to sales and gross profit.

Bonus

$468.33K

Board Justification

Annual cash bonus based on direct-to-customer net sales for 2018 and the Company’s gross profit for 2018

Other

$0.00

Board Justification

No other compensation reported for 2018.

Restricted Stock

$620.00K(166.67K Common Stock)

Board Justification

166,667 shares of Common Stock were awarded on June 22, 2018, which vested on December 20, 2018 in connection with an amendment to his employment agreement.

Performance Metrics

Direct-to-customer net sales for 2018 and the Company’s gross profit for 2018.

Other ChromaDex CEOs

Here are other CEOs of ChromaDex

Jeffrey Himmel

Ex-CEO of ChromaDex

January 2012 - June 2018